Current Updates on Trastuzumab Resistance in HER2 Overexpressing Breast Cancers.
Sign Up to like & getrecommendations! Published in 2019 at "Advances in experimental medicine and biology"
DOI: 10.1007/978-3-030-20301-6_10
Abstract: Trastuzumab represents the predominant therapy to target breast cancer subtype marked by HER2 amplification. It has been in use for two decades and its continued importance is underlined by recent FDA approvals of its biosimilar… read more here.
Keywords: trastuzumab resistance; breast; current updates; resistance her2 ... See more keywords